Background: Pregabalin is an anticonvulsant that is increasingly being prescribed as an adjunct for chronic pain (1, 2). However, it can be sedating and may augment central nervous system (CNS) depression in patients also receiving opioids (3). Because recent evidence shows that concomitant opioid and gabapentin use is associated with opioid-related mortality (4), understanding whether similar risks exist when pregabalin is coprescribed with opioids is essential.
for public drug coverage who received prescription opioids between 1 August 1997 and 31 December 2016. The study was approved by the Research Ethics Board of Sunnybrook Health Sciences Centre. The methods, data sources, and statistical analyses are consistent with those reported in our previous study examining the concomitant use of opioids and gabapentin (4). Any differences are described.
We identified a cohort of persons aged 15 to 105 years who received publicly funded opioid prescriptions over the study period. Case patients were defined as those who died of an opioid-related cause, excluding deaths determined to be suicide or homicide; the index date was the date of the opioid-related death. Each case patient was matched to up to 4 control participants on the basis of age (within 3 years), sex, index year (within 1 year), history of chronic kidney disease (within the previous 5 years), and Charlson comorbidity index score (within 0.2 SDs). In a sensitivity analysis, we also matched case patients with control participants on the basis of whether they were recently prescribed a benzodiazepine, an antidepressant, or other CNS depressant.
In the primary analysis, we defined recent exposure as receipt of a pregabalin prescription in the 120 days preceding the index date. In a secondary analysis, we explored whether a dose-response gradient was present, stratifying pregabalin exposure into low or moderate (≤300 mg/d) or high (>300 mg/d) doses. In a sensitivity analysis, we defined concomitant pregabalin exposure as receipt of a pregabalin prescription overlapping the index date. To test the specificity of our findings, we used concomitant use of nonsteroidal anti-inflammatory drugs as a predefined control exposure; these agents are not expected to increase the risk for opioid-related death. We used conditional logistic regression to estimate the association between opioidrelated death and concomitant pregabalin exposure, adjusting for characteristics that remained imbalanced after matching.
In total, 1417 case patients were identified and were matched to 5097 control participants. Case patients were more likely to have recently been prescribed other CNS depressants, receive more medications annually, and have more comorbidities than control participants (Table) .
After multivariable adjustment, concomitant exposure to pregabalin in the preceding 120 days was associated with significantly increased odds of opioid-related death compared with exposure to opioids alone (adjusted odds ratio [aOR], 1.68 [95% CI, 1.19 to 2.36]) ( Figure) . We observed consistent results in sensitivity analyses evaluating pregabalin use overlapping the index date (aOR, 1.81 [CI, 1.26 to 2.60]) and after matching on prior use of CNS depressants (aOR, 2.00 [CI, 1.39 to 2.88]). In the dose-response analysis, a high dose of pregabalin was associated with markedly increased odds of opioid-related death relative to no pregabalin exposure (aOR, 2.51 [CI, 1.24 to 5.06]), whereas a low or moderate dose of pregabalin was associated with lower but still significant odds of opioid-related death (aOR, 1.52 [CI, 1.04 to 2.22]). As expected, we found no association between coprescription of nonsteroidal anti-inflammatory drugs with opioids and risk for opioid-related mortality (aOR, 1.04 [CI, 0.90 to 1.19 
]).
Discussion: In this large, population-based study, we found compelling evidence for a potentially life-threatening drug-drug interaction involving pregabalin and opioids similar to that previously observed with gabapentin and opioids (4) . Because more than one half of Ontario residents who initiate pregabalin therapy are concurrently prescribed an opioid (5), this finding has important clinical implications. On the basis of these and earlier findings (4), we recommend caution when coprescribing gabapentinoids with opioids, particularly when the dose of either drug class is high. Furthermore, al- 
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All models were adjusted for recent exposure to gabapentin, selective serotonin reuptake inhibitors, other antidepressants, benzodiazepines, or other CNS depressants; number of medications dispensed in the past 6 mo; Charlson comorbidity index score; number of physicians and pharmacies prescribing and dispensing opioids in the past 6 mo; receipt of a long-acting opioid during the exposure window; and opioid dose. CNS = central nervous system; NSAID = nonsteroidal anti-inflammatory drug. * 1417 case patients and 5097 control participants. The reference group is those without recent exposure to pregabalin. † Recent exposure was defined as receipt of a prescription in the previous 120 d. ‡ 1199 case patients and 3935 control participants. The reference group is those without recent exposure to pregabalin. § The reference group is those without recent exposure to pregabalin. || >300 mg/d. ¶ ≤300 mg/d. ** The reference group is those without recent exposure to NSAIDs. though current product monographs for gabapentin contain warnings about serious adverse events when this agent is combined with opioids, those for pregabalin do not. The importance of our finding warrants a revision of the pregabalin product monographs. 
Note:
The funding source had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Mr. Greaves had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Background: Persons tend to estimate the likelihood of events, such as the risk for homicide versus suicide, in proportion to the ease with which they can retrieve examples of these incidents from memory (1) . Because the recency of personal experience and media coverage can influence this retrieval (1-3), misperceptions about the relative frequency of suicide versus homicide-the leading causes of intentionally inflicted (that is, violent) death from external causes (such as firearms)-may be common. In the United States, suicide is twice as common as homicide, and suicide by firearm is more common than homicide by firearm (4). However, no nationally representative study has assessed public perceptions of the relative frequency of these leading causes of violent death. This study addresses this subject. We hope that identifying the scope of actuarial misperceptions among the U.S. population in general and among those who own or live with firearm owners in particular might facilitate discussions about firearm ownership and storage.
Objective: To describe public misperceptions about the relative frequency of violent death by intent (homicide vs. suicide) and means (firearm vs. nonfirearm) at the national level.
Methods and Findings: We used data from the National Firearms Survey, a nationally representative Web-based survey of U.S. adults conducted by Growth for Knowledge in April 2015. Details are described elsewhere (5) . A total of 3949 participants were presented with 4 options on the intent and means of violent death (homicide with a gun, homicide with a weapon other than a gun, suicide with a gun, and suicide by a method other than a gun) and asked to rank order the frequency of these outcomes in their state in an average year (Supplement [available at Annals.org]).
We used the Centers for Disease Control and Prevention's Web-based Injury Statistics Query and Reporting System to rank these 4 options in each state between 2014 and 2015 (the year before the survey was conducted and the year that it was conducted, respectively) (4). Survey respondents were characterized by their ability to correctly rank the frequency of violent death in their state by intent and means.
Between 2014 and 2015, more suicides than homicides occurred in every state. Suicide by firearm was the most frequent cause of violent death in 29 states (Figure) . A total of 3811 respondents answered the question on the relative frequency of the intent and means of violent death in their state. Only 13.5% (95% CI, 11.5% to 15.8%) of U.S. adults correctly identified the most frequent cause of violent death (Table) . Furthermore, 20.0% (CI, 10.3% to 35.4%) of health care professionals among the 1880 respondents who reported their occupation and 12.4% (CI, 8.3% to 18.2%) of U.S. adults with a history of mental illness answered correctly. For violent deaths involving firearms, 25.9% (CI, 23.2% to 28.8%) correctly identified the most frequent intent. Correct identification did not vary by respondents' firearm ownership status.
Discussion: Suicide was more common than homicide in all states, and suicide by firearm was more common than homicide by firearm in all states except Illinois, Maryland, and New Jersey. However, most U.S. adults-including health care professionalsdid not identify the most frequent intent and means of violent death in their state. These findings are consistent with the wellestablished relationship between risk perception and the ease with which a pertinent categorical example can be summoned from memory, which in most persons is probably affected by the salience of homicides in media coverage (1, 2).
Our findings suggest that correcting misperceptions about the relative frequency of firearm-related violent deaths may make persons more cognizant of the actuarial risks to themselves and their family, thus creating new opportunities for prevention. If communication strategies could enhance the accuracy of perceived risk, some persons living in households with firearms might be motivated to remove these weapons from their home or at least keep unsafely stored firearms locked and unloaded to reduce access by potentially vulnerable family members. Future research should evaluate whether and under what circumstances promoting awareness about the relative frequency of suicide versus homicide (overall and by firearm), combined with evidence that firearm access increases the risk for 
